SHAREHOLDER ALERT: AZN REGI ATNX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / March 29, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Astrazeneca Plc (NYSE:AZN)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/astrazeneca-plc-loss-submission-form?prid=14190&wire=1
Lead Plaintiff Deadline: March 29, 2021
Class Period: May 21, 2020 - November 20, 2020
Allegations against AZN include that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.
Renewable Energy Group, Inc. (NASDAQ:REGI)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/renewable-energy-group-inc-loss-submission-form?prid=14190&wire=1
Lead Plaintiff Deadline: May 3, 2021
Class Period: May 3, 2018 - February 25, 2021
Allegations against REGI include that: (1) due to failures in the diesel additive system, petroleum diesel was not periodically added to certain loads by the Company and was instead added by the Company's customers; (2) as a result, Renewable Energy was not the proper claimant for certain BTC payments on biodiesel it sold between January 1, 2017 and September 30, 2020; (3) as a result, Renewable Energy's revenue and net income were overstated for certain periods; (4) there was a material weakness in the Company's internal control over financial reporting related to the purchase and use of the petroleum diesel gallons when blending with biodiesel; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Athenex, Inc. (NASDAQ:ATNX)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/athenex-inc-loss-submission-form?prid=14190&wire=1
Lead Plaintiff Deadline: May 3, 2021
Class Period: August 7, 2019 - February 26, 2021
Allegations against ATNX include that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/638044/SHAREHOLDER-ALERT-AZN-REGI-ATNX-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
